Cipla Limited (CIPLA.NS)
-NSE 399.65 
1.75(0.44%) Jan 28
| Prev Close: | 397.90 |
|---|
| Open: | 398.00 |
|---|
| Bid: | 399.65 |
|---|
| Ask: | 400.00 |
|---|
| 1y Target Est: | 435.79 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 398.00 - 404.40 |
|---|
| 52wk Range: | 300.00 - 435.00 |
|---|
| Volume: | 759,123 |
|---|
| Avg Vol (3m): | 1,154,380 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in INR.
Headlines
- India Said to Seek Review of U.S. Court Ruling Papers on Ranbaxyat Bloomberg(Wed, May 22)
- INDIA-PRESS-India to regulate prices of 652 drugs - Economic Timesat Reuters(Thu, May 16)
- Cipla Medpro shareholders back buyout by India's Ciplaat Reuters(Wed, May 15)
- Cipla Medpro shareholders approve buyout by India's Ciplaat Reuters(Wed, May 15)
- India's top generic drugmakers look to US as patents endat Reuters(Wed, May 8)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Fri, May 3)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Thu, May 2)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Tue, Apr 30)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Mon, Apr 29)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Fri, Apr 26)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Thu, Apr 25)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Wed, Apr 24)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Tue, Apr 23)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Mon, Apr 22)
- DIARY-South Africa corporate events to Nov 2013at Reuters(Fri, Apr 19)
Reports
- No Reports available for CIPLA.NS at this time.
Key Statistics
| Forward P/E (1 yr): | 19.62 |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-13)
: | 19.43 |
|---|
| Quarterly EPS Est
(Mar-13)
: | 4.57 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 1.00 |
|---|
Business Summary
Cipla Limited engages in the manufacture and sale of pharmaceutical products in India and internationally. The company offers various prescription pharmaceutical products for various diseases; and animal health care products, including active phar...
View More